tert-butyl ((S)-1-((2S,4R)-4-hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidin-1-yl)-3-methyl-1-oxobutan-2-yl)carbamate | 1448189-66-9

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: tert-butyl ((S)-1-((2S,4R)-4-hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidin-1-yl)-3-methyl-1-oxobutan-2-yl)carbamate
• 英文别名: VH032 analogue-2；tert-butyl N-[(2S)-1-[(2S,4R)-4-hydroxy-2-[[4-(4-methyl-1,3-thiazol-5-yl)phenyl]methylcarbamoyl]pyrrolidin-1-yl]-3-methyl-1-oxobutan-2-yl]carbamate
• CAS: 1448189-66-9
• 化学式: C₂₆H₃₆N₄O₅S
• 分子量: 516.662
• InChiKey: IBHOCLAWYSUEFY-HKBOAZHASA-N

物化性质

• 沸点：
  754.7±60.0 °C(Predicted)
• 密度：
  1.235±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  36
• 可旋转键数：
  9
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.54
• 拓扑面积：
  149
• 氢给体数：
  3
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  tert-butyl ((S)-1-((2S,4R)-4-hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidin-1-yl)-3-methyl-1-oxobutan-2-yl)carbamate 在 盐酸 作用下， 以 1,4-二氧六环 为溶剂， 反应 3.0h， 生成 (2S,4R)-1-((S)-2-amino-3-methylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide hydrochloride
  参考文献：
  名称：

  TANK结合激酶1的靶向靶向嵌合体（Von Hippel-Lindau-Recruiting蛋白水解）的鉴定和表征。

  摘要：

  靶向嵌合体的蛋白水解（PROTAC）是双功能分子，可将E3连接酶募集至目标蛋白质，以促进该蛋白质的泛素化和随后的降解。虽然靶向降解剂的领域还比较年轻，但这种方法成为分化和治疗现实的潜力很强，因此学术机构和制药机构现在都在进入这一有趣的研究领域。在本文中，我们描述了一种基于丝氨酸/苏氨酸激酶TANK结合激酶1（TBK1）识别降解子命中点的广泛适用的过程，并概括了与降解活动相关的关键结构要素。化合物3i命中率很高（TBK1 DC 50 = 12 nM，D max （= 96％）对相关激酶IKKε具有优异的选择性，该激酶还被用作化学工具，以评估TBK1作为突变K-Ras癌细胞中的靶标。

  DOI：

  10.1021/acs.jmedchem.7b00635
• 作为产物：
  描述：

  4-(4-甲基噻唑-5-基)苄胺 在 盐酸 、 甲醇 、 N,N-二异丙基乙胺 、 N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 5.0h， 生成 tert-butyl ((S)-1-((2S,4R)-4-hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidin-1-yl)-3-methyl-1-oxobutan-2-yl)carbamate
  参考文献：
  名称：

  TANK结合激酶1的靶向靶向嵌合体（Von Hippel-Lindau-Recruiting蛋白水解）的鉴定和表征。

  摘要：

  靶向嵌合体的蛋白水解（PROTAC）是双功能分子，可将E3连接酶募集至目标蛋白质，以促进该蛋白质的泛素化和随后的降解。虽然靶向降解剂的领域还比较年轻，但这种方法成为分化和治疗现实的潜力很强，因此学术机构和制药机构现在都在进入这一有趣的研究领域。在本文中，我们描述了一种基于丝氨酸/苏氨酸激酶TANK结合激酶1（TBK1）识别降解子命中点的广泛适用的过程，并概括了与降解活动相关的关键结构要素。化合物3i命中率很高（TBK1 DC 50 = 12 nM，D max （= 96％）对相关激酶IKKε具有优异的选择性，该激酶还被用作化学工具，以评估TBK1作为突变K-Ras癌细胞中的靶标。

  DOI：

  10.1021/acs.jmedchem.7b00635

文献信息

• [EN] BENZOTHIOPHENE DERIVATIVES AS ESTROGEN RECEPTOR INHIBITORS<br/>[FR] DÉRIVÉS BENZOTHIOPHÈNE COMME INHIBITEURS DU RÉCEPTEUR DES ŒSTROGÈNES
  申请人：GLAXOSMITHKLINE IP DEV LTD

  公开号：WO2015000867A1

  公开（公告）日：2015-01-08

  A compound of formula (I), or a pharmaceutically acceptable salt thereof, compositions, combinations and medicaments containing said compounds and processes for their preparation. The invention also relates to the use of said compounds, combinations, compositions and medicaments, for example as inhibitors of the activity of the estrogen receptor, including degrading the estrogen receptor, the treatment of diseases and conditions mediated by the estrogen receptor.

  式(I)的化合物，或其药学上可接受的盐，含有所述化合物的组合物、组合物和药物，以及其制备方法。该发明还涉及所述化合物、组合物、组合物和药物的用途，例如作为雌激素受体活性的抑制剂，包括降解雌激素受体，治疗由雌激素受体介导的疾病和症状。
• Compounds & Methods for the Enhanced Degradation of Targeted Proteins & Other Polypeptides by an E3 Ubiquitin Ligase
  申请人：YALE UNIVERSITY

  公开号：US20140356322A1

  公开（公告）日：2014-12-04

  The present invention relates to bifunctional compounds, which find utility as modulators of targeted ubiquitination, especially inhibitors of a variety of polypeptides and other proteins that are degraded and/or otherwise inhibited by bifunctional compounds of the present invention. In particular, the present invention is directed to compounds, which contain on one end a VHL ligand that binds to the ubiquitin ligase and on the other end a moiety that binds a target protein, such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of that protein. The present invention exhibits a broad range of pharmacological activities associated with compounds of the present invention, consistent with the degradation/inhibition of targeted polypeptides.

  本发明涉及双功能化合物，其作为靶向泛素化的调节剂具有实用性，特别是作为本发明的双功能化合物对各种被降解和/或受到抑制的多肽和其他蛋白质的抑制剂。具体而言，本发明涉及含有一端结合泛素连接酶的VHL配体，另一端结合靶蛋白的基团的化合物，使得靶蛋白靠近泛素连接酶以促使该蛋白的降解（和抑制）。本发明展示了与本发明化合物相关的广泛的药理活性范围，与靶向多肽的降解/抑制一致。
• ESTROGEN-RELATED RECEPTOR ALPHA BASED PROTAC COMPOUNDS AND ASSOCIATED METHODS OF USE
  申请人：Yale University

  公开号：US20160045607A1

  公开（公告）日：2016-02-18

  The present invention relates to bifunctional compounds, which find utility as modulators of targeted ubiquitination, especially inhibitors of a variety of polypeptides and other proteins which are degraded and/or otherwise inhibited by bifunctional compounds according to the present invention. In particular, the present invention is directed to compounds, which contain on one end a VHL ligand which binds to the ubiquitin ligase and on the other end a moiety which binds a target protein such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of that protein. The present invention exhibits a broad range of pharmacological activities associated with compounds according to the present invention, consistent with the degradation/inhibition of targeted polypeptides.

  本发明涉及双功能化合物，其作为靶向泛素化的调节剂具有实用性，特别是根据本发明抑制各种多肽和其他蛋白质的抑制剂。具体而言，本发明涉及一种在一端含有结合泛素连接酶的VHL配体，另一端含有结合靶蛋白的基团的化合物，使得靶蛋白位于靠近泛素连接酶以实现对该蛋白的降解（和抑制）。本发明展示了与根据本发明的化合物相关的广泛的药理活性范围，与靶向多肽的降解/抑制一致。
• [EN] PROTEOLYSIS TARGETING CHIMERAS (PROTACS) DIRECTED TO THE MODULATION OF THE ESTROGEN RECEPTOR<br/>[FR] CHIMÈRES CIBLANT LA PROTÉOLYSE (PROTACS) DIRIGÉES VERS LA MODULATION DU RÉCEPTEUR DES ŒSTROGÈNES
  申请人：GLAXOSMITHKLINE IP DEV LTD

  公开号：WO2014108452A1

  公开（公告）日：2014-07-17

  A compound of formula (I): or a pharmaceutically acceptable salt thereof, compositions, combinations and medicaments containing said compounds and processes for their preparation. The invention also relates to the use of said compounds, combinations, compositions and medicaments, for example as inhibitors of the activity of the estrogen receptor, including degrading the estrogen receptor, the treatment of diseases and conditions mediated by the estrogen receptor.

  公式（I）的化合物：或其药用可接受盐，含有所述化合物的组合物、组合物和药物以及其制备方法。本发明还涉及所述化合物、组合物、组合物和药物的用途，例如作为雌激素受体活性的抑制剂，包括降解雌激素受体，治疗由雌激素受体介导的疾病和症状。
• NOVEL COMPOUNDS
  申请人：GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED

  公开号：US20160136230A1

  公开（公告）日：2016-05-19

  A compound of formula (I): or a pharmaceutically acceptable salt thereof, compositions, combinations and medicaments containing said compounds and processes for their preparation. The invention also relates to the use of said compounds, combinations, compositions and medicaments, for example as inhibitors of the activity of the estrogen receptor, including degrading the estrogen receptor, the treatment of diseases and conditions mediated by the estrogen receptor.

  式（I）的化合物：或其药用可接受的盐，包含上述化合物的组合物、组合物和药物，以及其制备方法。本发明还涉及上述化合物、组合物、组合物和药物的用途，例如作为雌激素受体活性抑制剂，包括降解雌激素受体，用于治疗由雌激素受体介导的疾病和症状。